In addition to conventional chemoradiation and chemotherapy approaches, the ADELE trial is evaluating the potential of an immune checkpoint inhibitor named Tislelizumab (PD-1 inhibitor), in combination with chemotherapy as a post-chemoradiation intervention for high-risk endometrial cancer cases [116]. Here, PDCD1 is linked to endometrial cancer.